Esteemed Industry Leaders to be Honored for Contributions to California’s Thriving Life Sciences Sector on Nov. 10
The Pantheon Awards program, now in its 14th year, brings together more than 600 industry pioneers – including innovators, thought leaders, investors and educators
CLSA was greatly honored to welcome Dr. Robert Califf as the keynote speaker at our recent Evening with Thought Leaders in Los Angeles. Dr. Califf has had an extraordinarily impressive career as a cardiologist, Commissioner of the Food & Drug Administration (FDA), and now as a researcher with Duke University and advisor at Verily, an Alphabet company.
On Sept. 11, Senate Bill 790 (McGuire) was placed on the inactive file, meaning that, while the bill is dead for this year, it will be eligible to be heard again once the legislature reconvenes in early January 2018.
California Life Sciences Association (CLSA), the statewide public policy and business leadership trade association representing California’s life sciences industry, today announced winners of the 2017 Pantheon DiNA Awards, a distinguished awards program honoring innovation and excellence within California’s life sciences sector.
Despite the best efforts of CLSA and its partner trade associations, Senate Bill 17 (Hernandez) has reached the Governor’s desk. Gov. Brown has until Oct. 13 to sign the bill for it to become law. If it’s signed, the advance notice requirements, as discussed below, would become effective on Jan. 1, 2018.
This September, CLSA participated in the 4th Annual Rally for Medical Research Hill Day to support funding for the NIH, and to continue efforts to make funding biomedical research a national priority.
On Sept. 12, the Sonoma Board of Supervisors held a new hearing on take back ordinance options for the County. At the Board’s last hearing on the subject in October of 2016, it had directed staff to begin drafting an ordinance for drug take back while also researching the potential need and possibility of including the disposal of sharps into the legislation.
CLSA’s Brett Johnson provides analysis to The Mercury News on Senate Bill 17, legislation pending in Sacramento that will harm patient access to care and biotechnology innovation in California.
“Californians have legitimate concerns about access to affordable drugs, but SB 17 does not address them. It is a bad deal for business and does nothing to benefit patients.” – William J. Newell, CEO, Sutro Biopharma & Vice Chairman, California Life Sciences Association.